 <h1>Eribulin Side Effects</h1><ul class="ddc-anchor-links"><li>Consumer</li>
<li>Professional</li></ul><h2>In Summary</h2><p><b>Commonly reported side effects of eribulin include:</b> urinary tract infection, severe neutropenia, alopecia, anemia, arthralgia, asthenia, back pain, cough, fatigue, headache, myalgia, neutropenia, ostealgia, paresthesia, peripheral neuropathy, peripheral sensory neuropathy, polyneuropathy, weight loss, neuropathy, and anorexia. <b>Other side effects include:</b> febrile neutropenia, and peripheral motor neuropathy.  See below for a comprehensive list of adverse effects.</p><h2 class="ddc-anchor-offset" id="consumer">For the Consumer</h2><p><i>Applies to eribulin: intravenous solution</i></p><h3>Side effects requiring immediate medical attention</h3><p>Along with its needed effects, eribulin may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.</p><p>
<i>Check with your doctor or nurse immediately</i> if any of the following side effects occur while taking eribulin:</p><p>
<i>More common</i>
</p><ul>
<li>Black, tarry stools</li>
<li>bladder pain</li>
<li>bloating or swelling of the face, arms, hands, lower legs, or feet</li>
<li>bloody or cloudy urine</li>
<li>body aches or pain</li>
<li>burning, numbness, tingling, or painful sensations</li>
<li>chills</li>
<li>convulsions</li>
<li>cough</li>
<li>decreased urine</li>
<li>decreased weight</li>
<li>difficult or labored breathing</li>
<li>difficult, burning, or painful urination</li>
<li>dry mouth</li>
<li>ear congestion</li>
<li>fever</li>
<li>frequent urge to urinate</li>
<li>headache</li>
<li>increased thirst</li>
<li>irregular heartbeat</li>
<li>loss of appetite</li>
<li>loss of voice</li>
<li>lower back or side pain</li>
<li>mood changes</li>
<li>muscle pain or cramps</li>
<li>nasal congestion</li>
<li>nausea or vomiting</li>
<li>numbness or tingling in the hands, feet, or lips</li>
<li>pale skin</li>
<li>rapid weight gain</li>
<li>runny nose</li>
<li>sneezing</li>
<li>sore throat</li>
<li>tightness in the chest</li>
<li>troubled breathing with exertion</li>
<li>ulcers, sores, or white spots in the mouth</li>
<li>unsteadiness or awkwardness</li>
<li>unusual bleeding or bruising</li>
<li>unusual tiredness or weakness</li>
<li>unusual weight gain or loss</li>
<li>weakness in the arms, hands, legs, or feet</li>
</ul><p>
<i>Incidence not known</i>
</p><ul>
<li>Fainting</li>
<li>irregular heartbeat, recurrent</li>
</ul><h3>Side effects not requiring immediate medical attention</h3><p>Some side effects of eribulin may occur that usually <b>do not need medical attention</b>. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects.</p><p>Check with your health care professional if any of the following side effects <b>continue or are bothersome</b> or if you have any questions about them:</p><p>
<i>More common</i>
</p><ul>
<li>Acid or sour stomach</li>
<li>back pain</li>
<li>belching</li>
<li>bone pain</li>
<li>change in taste</li>
<li>cracked lips</li>
<li>depression</li>
<li>diarrhea</li>
<li>difficulty having a bowel movement (stool)</li>
<li>difficulty with moving</li>
<li>difficulty with swallowing</li>
<li>dizziness</li>
<li>hair loss or thinning of the hair</li>
<li>heartburn</li>
<li>indigestion</li>
<li>lack or loss of strength</li>
<li>loss of taste</li>
<li>muscle spasm or weakness</li>
<li>muscle stiffness</li>
<li>pain in the arms or legs</li>
<li>pain in the joints</li>
<li>rash</li>
<li>sores, ulcers, or white spots on the lips, tongue, or inside the mouth</li>
<li>stomach discomfort, upset, or pain</li>
<li>swelling or inflammation of the mouth</li>
<li>trouble sleeping</li>
<li>watering of the eyes</li>
<li>weight loss</li>
</ul><p>
<!-- end intravenous solution --><div class="related-links"><svg aria-hidden="true" class="ddc-icon ddc-icon-info" focusable="false" height="22" viewbox="0 0 24 24" width="22" xmlns="http://www.w3.org/2000/svg"><path d="M14 2H6c-1.1 0-1.99.9-1.99 2L4 20c0 1.1.89 2 1.99 2H18c1.1 0 2-.9 2-2V8l-6-6zm2 16H8v-2h8v2zm0-4H8v-2h8v2zm-3-5V3.5L18.5 9H13z"></path></svg> <span>Managing side effects <span class="ddc-text-nowrap">(general information)</span></span></div>
<h2 class="ddc-anchor-offset" id="professional">For Healthcare Professionals</h2><p><i>Applies to eribulin: intravenous solution</i></p><h3>Hematologic</h3><p>In one study, grade 3 neutropenia occurred in 28% of patients, 29% experience grade 4 neutropenia, and 5% of patients experienced febrile neutropenia.  Dose reductions due to neutropenia occurred in 12% of patients and discontinuation was required in less than 1% of patients.  Grade 3 or greater thrombocytopenia was reported in 1% of patients.  Granulocyte colony-stimulating factor or granulocyte-macrophage colony-stimulating factor was used in 19% of patients treated with this drug.<sup>[Ref]</sup></p><p><b>Very common</b> (10% or more): Neutropenia (up to 82%), anemia (up to 58%) </p>
<p><b>Very common</b> (10% or more): Urinary tract infection (up to 10%)</p>
<p><b>Uncommon</b> (0.1% to 1%): Dysuria, hematuria, proteinuria, hematuria, leukopenia, lymphopenia<sup>[Ref]</sup></p><h3>Nervous system</h3><p><b>Very common</b> (10% or more): Peripheral neuropathy (up to 35%)</p>
<p><b>Common</b> (1% to 10%): Dysgeusia, dizziness, hypoesthesia, lethargy, neurotoxicity, polyneuropathy, peripheral sensory neuropathy, paresthesia<sup>[Ref]</sup></p><h3>Gastrointestinal</h3><p><b>Very common</b> (10% or more): Nausea (up to 35%), constipation (up to 25%), diarrhea (up to 18%), vomiting (up to 18%)</p>
<p><b>Common</b> (1% to 10%): Abdominal pain, stomatitis, dry mouth, dyspepsia, gastroesophageal reflux disease, mouth ulceration, mucosal inflammation, abdominal distension</p>
<p><b>Postmarketing reports</b>: Pancreatitis<sup>[Ref]</sup></p><h3>Cardiovascular</h3><p><b>Common</b> (1% to 10%): QT prolongation, tachycardia, peripheral edema<sup>[Ref]</sup></p><h3>Dermatologic</h3><p><b>Very common</b> (10% or more): Alopecia (up to 45%)</p>
<p><b>Common</b> (1% to 10%): Rash, pruritus, nail disorder, night sweats, palmar plantar erythrodysesthesia, dry skin, erythema, hyperhidrosis<sup>[Ref]</sup></p><h3>Genitourinary</h3><p><b>Very common</b> (10% or more): Urinary tract infection (up to 10%)</p>
<p><b>Uncommon</b> (0.1% to 1%): Dysuria, hematuria, proteinuria</p>
<p></p>
<p>v<sup>[Ref]</sup></p><h3>Hepatic</h3><p><b>Common</b> (1% to 10%): Alanine aminotransferase increased, aspartate aminotransferase increased, gamma glutamyl transferase increased, hyperbilirubinemia<sup>[Ref]</sup></p><h3>Metabolic</h3><p><b>Very common</b> (10% or more): Weight decreased (up to 21%), anorexia (up to 20%)</p>
<p><b>Common</b> (1% to 10%): Hypokalemia<sup>[Ref]</sup></p><h3>Musculoskeletal</h3><p><b>Very common</b> (10% or more): Arthralgia/Myalgia (up to 22%), back pain (up to 16%), bone pain (up to 12%), pain in extremity (up to 11%)</p>
<p><b>Common</b> (1% to 10%): Muscle spasms, musculoskeletal pain, musculoskeletal chest pain<sup>[Ref]</sup></p><h3>Ocular</h3><p><b>Common</b> (1% to 10%): Lacrimation increased, conjunctivitis<sup>[Ref]</sup></p><h3>Other</h3><p><b>Very common</b> (10% or more): Asthenia/Fatigue (up to 54%), pyrexia (up to 21%) </p>
<p><b>Common</b> (1% to 10%): Disseminated intravascular coagulation, oral herpes, mucosal inflammation, hot flushes, pain, chills, peripheral neuropathy, headache</p>
<p><b>Frequency not reported</b>: Tinnitus<sup>[Ref]</sup></p><h3>Psychiatric</h3><p><b>Very common</b> (10% or more): Headache</p>
<p><b>Common</b> (1% to 10%): Insomnia, depression<sup>[Ref]</sup></p><h3>Respiratory</h3><p><b>Very common</b> (10% or more): Dyspnea (up to 16%), cough (up to 14%)</p>
<p><b>Rare</b> (less than 0.1%): Upper respiratory tract infection, nasopharyngitis, rhinitis</p>
<p><b>Frequency not reported</b>: Oropharyngeal pain, epistaxis, rhinorrhea<sup>[Ref]</sup></p><h3>Immunologic</h3><p><b>Very common</b> (10% or more):</p>
<p><b>Common</b> (1% to 10%): Oral candidiasis, influenza-like illness, mucosal inflammation</p>
<p><b>Postmarketing reports</b>: Pneumonia, sepsis/neutropenic sepsis<sup>[Ref]</sup></p><div class="referenceList"><h4 id="refs">References</h4><p id="ref_1">1. Cerner Multum,  Inc. "UK Summary of Product Characteristics." O 0</p><p id="ref_2">2. Pharmaceutical Society of Australia "APPGuide online. Australian prescription products guide online. Available from: URL: http://www.appco.com.au/appguide/default.asp."   ([2006]):</p><p id="ref_3">3. "Product Information. Halaven (eribulin)." Eisai Inc, Teaneck, NJ. </p></div>
<div class="more-resources" id="moreResources">
<h2>More about eribulin</h2>
<ul class="more-resources-list more-resources-list-general">
<li>During Pregnancy</li>
<li>Dosage Information</li>
<li>Drug Interactions</li>
<li>En Espa√±ol</li>
<li>10 Reviews</li>
<li>Drug class: mitotic inhibitors</li>
</ul>
<h3>Consumer resources</h3>
<ul class="more-resources-list more-resources-list-consumer">
<li>Patient Information</li>
<li>Eribulin Intravenous &lt;span&gt;(Advanced Reading)&lt;/span&gt;</li>
</ul>
<dl class="more-resources-other-brands more-resources-other-brands-consumer"><dt>Other brands</dt><dd>Halaven</dd></dl>
<h3>Professional resources</h3>
<ul class="more-resources-list more-resources-list-professional">
<li>Prescribing Information</li>
<li data-more-config-id="list-data-resources-professional">... +1 more</li>
</ul>
<h3>Related treatment guides</h3>
<ul class="more-resources-list more-resources-list-conditions">
<li>Liposarcoma</li>
<li>Breast Cancer</li>
<li>Breast Cancer, Metastatic</li>
</ul>
</div>
<h2>Further information</h2><p class="ddc-disclaimer">Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.</p>
<p>Some side effects may not be reported. You may report them to the FDA.</p>
<p class="ddc-disclaimer-link">Medical Disclaimer</p>
<script>
function showRefs(refs) {
	if (!document.querySelectorAll) {
		return;
	}

	var referenceIds = refs ? refs.split(',') : [];
	var referenceTitle = referenceIds.length
		 ? "References relevant to chosen section <span class='ddc-text-size-small font-weight-normal'>(<a href='#refs' onclick='showRefs(\"\"); return false;'>Show all references</a>)</span>"
		 : "References";
	document.getElementById('refs').innerHTML = referenceTitle;

	// Show/hide reference items
	var referenceList = document.querySelectorAll('.referenceList p');
	referenceList.forEach(function(item) {
		var id = item.id.replace('ref_', '');
		if (!referenceIds.length || referenceIds.includes(id)) {
			item.style.display = 'block';
		}
		else {
			item.style.display = 'none';
		}
	});
}
</script>
</p><h2 class="ddc-anchor-offset" id="professional">For Healthcare Professionals</h2><p><i>Applies to eribulin: intravenous solution</i></p><h3>Hematologic</h3><p>In one study, grade 3 neutropenia occurred in 28% of patients, 29% experience grade 4 neutropenia, and 5% of patients experienced febrile neutropenia.  Dose reductions due to neutropenia occurred in 12% of patients and discontinuation was required in less than 1% of patients.  Grade 3 or greater thrombocytopenia was reported in 1% of patients.  Granulocyte colony-stimulating factor or granulocyte-macrophage colony-stimulating factor was used in 19% of patients treated with this drug.<sup>[Ref]</sup></p><p><b>Very common</b> (10% or more): Neutropenia (up to 82%), anemia (up to 58%) </p><p><b>Very common</b> (10% or more): Urinary tract infection (up to 10%)</p><p><b>Uncommon</b> (0.1% to 1%): Dysuria, hematuria, proteinuria, hematuria, leukopenia, lymphopenia<sup>[Ref]</sup></p><h3>Nervous system</h3><p><b>Very common</b> (10% or more): Peripheral neuropathy (up to 35%)</p><p><b>Common</b> (1% to 10%): Dysgeusia, dizziness, hypoesthesia, lethargy, neurotoxicity, polyneuropathy, peripheral sensory neuropathy, paresthesia<sup>[Ref]</sup></p><h3>Gastrointestinal</h3><p><b>Very common</b> (10% or more): Nausea (up to 35%), constipation (up to 25%), diarrhea (up to 18%), vomiting (up to 18%)</p><p><b>Common</b> (1% to 10%): Abdominal pain, stomatitis, dry mouth, dyspepsia, gastroesophageal reflux disease, mouth ulceration, mucosal inflammation, abdominal distension</p><p><b>Postmarketing reports</b>: Pancreatitis<sup>[Ref]</sup></p><h3>Cardiovascular</h3><p><b>Common</b> (1% to 10%): QT prolongation, tachycardia, peripheral edema<sup>[Ref]</sup></p><h3>Dermatologic</h3><p><b>Very common</b> (10% or more): Alopecia (up to 45%)</p><p><b>Common</b> (1% to 10%): Rash, pruritus, nail disorder, night sweats, palmar plantar erythrodysesthesia, dry skin, erythema, hyperhidrosis<sup>[Ref]</sup></p><h3>Genitourinary</h3><p><b>Very common</b> (10% or more): Urinary tract infection (up to 10%)</p><p><b>Uncommon</b> (0.1% to 1%): Dysuria, hematuria, proteinuria</p><p></p><p>v<sup>[Ref]</sup></p><h3>Hepatic</h3><p><b>Common</b> (1% to 10%): Alanine aminotransferase increased, aspartate aminotransferase increased, gamma glutamyl transferase increased, hyperbilirubinemia<sup>[Ref]</sup></p><h3>Metabolic</h3><p><b>Very common</b> (10% or more): Weight decreased (up to 21%), anorexia (up to 20%)</p><p><b>Common</b> (1% to 10%): Hypokalemia<sup>[Ref]</sup></p><h3>Musculoskeletal</h3><p><b>Very common</b> (10% or more): Arthralgia/Myalgia (up to 22%), back pain (up to 16%), bone pain (up to 12%), pain in extremity (up to 11%)</p><p><b>Common</b> (1% to 10%): Muscle spasms, musculoskeletal pain, musculoskeletal chest pain<sup>[Ref]</sup></p><h3>Ocular</h3><p><b>Common</b> (1% to 10%): Lacrimation increased, conjunctivitis<sup>[Ref]</sup></p><h3>Other</h3><p><b>Very common</b> (10% or more): Asthenia/Fatigue (up to 54%), pyrexia (up to 21%) </p><p><b>Common</b> (1% to 10%): Disseminated intravascular coagulation, oral herpes, mucosal inflammation, hot flushes, pain, chills, peripheral neuropathy, headache</p><p><b>Frequency not reported</b>: Tinnitus<sup>[Ref]</sup></p><h3>Psychiatric</h3><p><b>Very common</b> (10% or more): Headache</p><p><b>Common</b> (1% to 10%): Insomnia, depression<sup>[Ref]</sup></p><h3>Respiratory</h3><p><b>Very common</b> (10% or more): Dyspnea (up to 16%), cough (up to 14%)</p><p><b>Rare</b> (less than 0.1%): Upper respiratory tract infection, nasopharyngitis, rhinitis</p><p><b>Frequency not reported</b>: Oropharyngeal pain, epistaxis, rhinorrhea<sup>[Ref]</sup></p><h3>Immunologic</h3><p><b>Very common</b> (10% or more):</p><p><b>Common</b> (1% to 10%): Oral candidiasis, influenza-like illness, mucosal inflammation</p><p><b>Postmarketing reports</b>: Pneumonia, sepsis/neutropenic sepsis<sup>[Ref]</sup></p><p id="ref_1">1. Cerner Multum,  Inc. "UK Summary of Product Characteristics." O 0</p><p id="ref_2">2. Pharmaceutical Society of Australia "APPGuide online. Australian prescription products guide online. Available from: URL: http://www.appco.com.au/appguide/default.asp."   ([2006]):</p><p id="ref_3">3. "Product Information. Halaven (eribulin)." Eisai Inc, Teaneck, NJ. </p><h2>More about eribulin</h2><ul class="more-resources-list more-resources-list-general">
<li>During Pregnancy</li>
<li>Dosage Information</li>
<li>Drug Interactions</li>
<li>En Espa√±ol</li>
<li>10 Reviews</li>
<li>Drug class: mitotic inhibitors</li>
</ul><h3>Consumer resources</h3><ul class="more-resources-list more-resources-list-consumer">
<li>Patient Information</li>
<li>Eribulin Intravenous &lt;span&gt;(Advanced Reading)&lt;/span&gt;</li>
</ul><h3>Professional resources</h3><ul class="more-resources-list more-resources-list-professional">
<li>Prescribing Information</li>
<li data-more-config-id="list-data-resources-professional">... +1 more</li>
</ul><h3>Related treatment guides</h3><ul class="more-resources-list more-resources-list-conditions">
<li>Liposarcoma</li>
<li>Breast Cancer</li>
<li>Breast Cancer, Metastatic</li>
</ul><h2>Further information</h2><p class="ddc-disclaimer">Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.</p><p>Some side effects may not be reported. You may report them to the FDA.</p><p class="ddc-disclaimer-link">Medical Disclaimer</p>